A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Kura Oncology, Inc.
Eastern Cooperative Oncology Group
Essen Biotech
Fred Hutchinson Cancer Center
University of Arizona
UNC Lineberger Comprehensive Cancer Center
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Washington University School of Medicine
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Medical University of Vienna
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
Roswell Park Cancer Institute
BTG International Inc.
National Institutes of Health Clinical Center (CC)
Gilead Sciences
Roswell Park Cancer Institute
Novartis
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Case Comprehensive Cancer Center
Celgene
Acrotech Biopharma Inc.
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
University of Maryland, Baltimore
University of Maryland, Baltimore
University of Maryland, Baltimore
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Albert Einstein College of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
University of Rochester
Columbia University
Alliance for Clinical Trials in Oncology